The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide? [0.03%]
吸入皮质类固醇的疗效和安全性：我们是否忽略了环索奈德潜在的优势？
Thys van der Molen,Janwillem W H Kocks
Thys van der Molen
Development and validation of a model to predict the 10-year risk of general practitioner-recorded COPD [0.03%]
用于预测全科医生记录的COPD 10年风险模型的建立和验证
Daniel Kotz,Colin R Simpson,Wolfgang Viechtbauer et al.
Daniel Kotz et al.
Background: There is increasing interest in the earlier detection of, and intervention in, patients at highest risk of developing chronic obstructive pulmonary disease (COPD). ...
Randomized Controlled Trial
NPJ primary care respiratory medicine. 2014 May 20:24:14011. DOI:10.1038/npjpcrm.2014.11 2014
Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: a randomised parallel-group study [0.03%]
与布地奈德相比，环索奈德在轻中度哮喘序贯降级治疗方案中的疗效研究：随机平行分组试验
Kuo-Chin Chiu,Yen-Li Chou,Jeng-Yuan Hsu et al.
Kuo-Chin Chiu et al.
Background: Inhaled corticosteroids (ICSs) are widely used in asthma control. Ciclesonide (CIC) is an ICS with on-site lung activation for potent anti-inflammatory activity. ...
Randomized Controlled Trial
NPJ primary care respiratory medicine. 2014 May 20:24:14010. DOI:10.1038/npjpcrm.2014.10 2014